Lexeo Therapeutics, Inc. Common Stock (LXEO)
Automate Your Wheel Strategy on LXEO
With Tiblio's Option Bot, you can configure your own wheel strategy including LXEO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LXEO
- Rev/Share 0.0446
- Book/Share 3.1721
- PB 2.0397
- Debt/Equity 0.0645
- CurrentRatio 4.4333
- ROIC -0.8388
- MktCap 214784590.0
- FreeCF/Share -2.1855
- PFCF -2.2554
- PE -2.4693
- Debt/Assets 0.0506
- DivYield 0
- ROE -0.9465
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | LXEO | Oppenheimer | -- | Outperform | -- | $20 | July 31, 2025 |
News
Lexeo: Maintaining Buy Rating Based On FDA Accelerated Approval Feedback
Published: October 07, 2025 by: Seeking Alpha
Sentiment: Positive
Lexeo Therapeutics received positive FDA feedback, enabling a faster path to Accelerated Approval for LX2006 in FA cardiomyopathy. Pooled phase 1/2 interim data for LX2006 show LVMI improvements well above FDA thresholds at 6 and 12 months, supporting efficacy. LXEO maintains strong financials, with cash reserves expected to fund operations into 2028 after a recent $80 million private placement.
Read More
Lexeo Therapeutics, Inc. - Special Call
Published: October 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Lexeo Therapeutics, Inc. - Special Call Company Participants Louis Tamayo - CFO & Principal Accounting Officer R. Townsend - CEO & Director Sandi Tai - Chief Development Officer Eric Adler - Chief Medical Officer & Head of Research Conference Call Participants Tessa Romero - JPMorgan Chase & Co, Research Division Brian Skorney - Robert W.
Read More
Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned registrational study LX2006 registrational study expected to begin by early 2026; commencing enrollment in prospective natural history study, CLARITY-FA, in Q2 2025 to serve as concurrent external control Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently enrolling patients in Cohort 3; interim clinical data update on track for second half of 2025 Redeployed $20 million to focus on clinical-stage programs; cash, cash equivalents and investments of $106.9 million expected to provide operational runway into …
Read More
Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement
Published: May 05, 2025 by: Seeking Alpha
Sentiment: Positive
Lexeo Therapeutics, Inc. established further positive interim data from phase 1/2 SUNRISE-FA study using LX2006 for the treatment of patients with Friedreich's Ataxia Cardiomyopathy. Pivotal LXEO registration study of LX2006 for the treatment of patients with Friedreich's Ataxia expected to start in 2026, with data release possible in 2027. The global Friedreich's Ataxia market is projected to reach $3.49 billion by the end of 2034.
Read More
Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its AAV manufacturing approach will be presented at the 28 th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 13-17, 2025 in New Orleans, LA. “The data being presented at ASGCT underscore the strength of our industry-leading capabilities in AAV manufacturing with high yield and high quality,” said José Manuel Otero, Chief Technical Officer of Lexeo Therapeutics.
Read More
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Additional alignment with FDA on LX2006 planned pivotal study including protein expression co-primary endpoint: based on improvements in LVMI across participants with abnormal LVMI at baseline, frataxin expression to be evaluated for any increase from baseline rather than numerical threshold Interim update from cohort 1 of LX2020 HEROIC-PKP2 Phase 1/2 trial: observed 71% and 115% increases in PKP2 protein expression in first two post-treatment biopsies; first participant evaluated 6-months after dosing experienced 67% reduction in premature ventricular contractions (PVCs) Completed enrollment of cohort 2 of LX2020 HEROIC-PKP2 Phase 1/2 trial; interim clinical data update expected in second half of 2025 …
Read More
About Lexeo Therapeutics, Inc. Common Stock (LXEO)
- IPO Date 2023-11-03
- Website https://www.lexeotx.com
- Industry Biotechnology
- CEO R. Nolan Townsend
- Employees 75